Article
Pfizer's breast cancer drug Ibrance fails late-stage study
Rating:
0.0
Views:
71
Likes:
1
Library:
1
The latest development comes after an independent data monitoring committee said in May a similar trial comparing Ibrance plus an endocrine therapy to a standalone endocrine therapy to treat early-stage breast cancer was unlikely to meet the main goal. Ibrance is already approved in the United States to treat certain adult patients with advanced breast […]
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value